SCHEMBL25410168

SCHEMBL25410168

Cc1ccc(S(=O)(=O)N2C[C@H](Cc3ccc(F)cc3)c3c(C=O)cccc32)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 2/20 0.38
▸ BCHE P06276 1/20 0.38
▸ TP53 P04637 2/20 0.38
▸ KMT2A Q03164 4/20 0.37
▸ MEN1 O00255 3/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ UBE2N P61088 1/20 0.35
▸ KCNN4 O15554 1/20 0.35
▸ KCNA3 P22001 1/20 0.35
▸ LMNA P02545 2/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ FKBP1A P62942 1/20 0.35
▸ THRB P10828 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25410176 1.00 ACHE (0.38) ACHEBCHETP53KMT2AMEN1
SCHEMBL25413830 0.95 KDM4E (0.39) ACHESMN1; SMN2KDM4EUBE2NKCNN4
SCHEMBL25413834 0.95 KDM4E (0.39) ACHESMN1; SMN2KDM4EUBE2NKCNN4
SCHEMBL25411441 0.91 ALDH1A1 (0.40) ACHEBCHESMN1; SMN2NPSR1KDM4E
SCHEMBL25411450 0.91 ALDH1A1 (0.40) ACHEBCHESMN1; SMN2NPSR1KDM4E
SCHEMBL25413763 0.90 ALDH1A1 (0.38) SMN1; SMN2NPSR1KDM4EUBE2NKCNN4
SCHEMBL25413769 0.90 ALDH1A1 (0.38) SMN1; SMN2NPSR1KDM4EUBE2NKCNN4
SCHEMBL25413077 0.89 GAA (0.43) ACHEBCHEKMT2AMEN1SMN1; SMN2
SCHEMBL25413083 0.89 GAA (0.43) ACHEBCHEKMT2AMEN1SMN1; SMN2
SCHEMBL25413130 0.88 CA1 (0.42) ACHEBCHEKMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230278959-A1 Synthesis of Optically Active Indoline Derivatives Via Ruthenium(II)-Catalyzed Enantioselective C-H Functionalization MISSISSIPPI STATE UNIVERSITY 2023-09-07 — — US disclosed
US-20230278959-A1 Synthesis of Optically Active Indoline Derivatives Via Ruthenium(II)-Catalyzed Enantioselective C-H Functionalization MISSISSIPPI STATE UNIVERSITY 2023-09-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278959-A1 Synthesis of Optically Active Indoline Derivatives Via Ruthenium(II)-Catalyzed Enantioselective C-H Functionalization INMT, IDO2, WEE2 ACHE 470/4885BCHE 196/4885TP53 2794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback